A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea
NCT ID: NCT00667173
Last Updated: 2012-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
140 participants
INTERVENTIONAL
2007-11-30
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea
NCT01828177
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
NCT01025635
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355471
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
NCT00617903
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01318733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
IDP-115
Topical application for 12 weeks
2
Vehicle
Topical application for 12 weeks
3
Vehicle
Topical application for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IDP-115
Topical application for 12 weeks
Vehicle
Topical application for 12 weeks
Vehicle
Topical application for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of inflammatory lesions
Exclusion Criteria
* Known history of photosensitivity disorders (such as lupus erythematosus or polymorphous light eruption)
* Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dow Pharmaceutical Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Affiliated Research Center, Inc.
Huntsville, Alabama, United States
Therapeutics Clinical Research
San Diego, California, United States
Solano Clinical Research
Vallejo, California, United States
Cherry Creek Dermatology Research Inc.
Denver, Colorado, United States
FXM Research Corp.
Miami, Florida, United States
MedaPhase Inc.
Newnan, Georgia, United States
Henry Ford Medical Center
Detroit, Michigan, United States
Academic Dermatology Associates
Albuquerque, New Mexico, United States
University Dermatology Consultants, Inc.
Cincinnati, Ohio, United States
DermResearch, Inc.
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DPSI-IDP-115-P2-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.